Content about Neurological disorders

February 26, 2014

A study released Wednesday by Rhonda Patrick and Bruce Ames of Children's Hospital Oakland Research Institute demonstrated the impact that vitamin D may have on social behavior associated with Autism Spectrum Disorder.

OAKLAND, Calif. — A study released Wednesday by Rhonda Patrick and Bruce Ames of Children's Hospital Oakland Research Institute demonstrated the impact that vitamin D may have on social behavior associated with Autism Spectrum Disorder. 

January 24, 2014

Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated that aspirin intake correlates with halted growth of vestibular schwannomas, also known as acoustic neuromas, a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

BOSTON — Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated that aspirin intake correlates with halted growth of vestibular schwannomas, also known as acoustic neuromas, a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

August 21, 2013

Rite Aid's philanthropic arm has donated $10,000 to benefit children with autism, according to published reports.

NEW YORK — Rite Aid's philanthropic arm has donated $10,000 to benefit children with autism, according to published reports.

The Macomb County, Mich., Daily reported that the Rite Aid Foundation had made the donation to Sterling Heights, Mich., for use in creating a "Play Place for Autistic Children."

August 1, 2013

Walgreens opened a new training facility here in partnership with Have Dreams, an advocacy group for children with autism, according to a story published Wednesday by Evanston Now.

The training involves setting up displays, working the cash register, stocking and organizing shelves and other skill sets that enable the autistic students to make a contribution to a store’s operations.

EVANSTON, Ill. — Walgreens opened a new training facility here in partnership with Have Dreams, an advocacy group for children with autism, according to a story published Wednesday by Evanston Now

The training involves setting up displays, working the cash register, stocking and organizing shelves and other skill sets that enable the autistic students to make a contribution to a store’s operations.

July 1, 2013

More than half of Americans suffer from motion sickness, according to a recent survey conducted on behalf of Prestige Brands' Dramamine, with as many as 60% indicating that they most often suffer while riding as a passenger in a car.

TARRYTOWN, N.Y. — More than half of Americans suffer from motion sickness, according to a recent survey conducted on behalf of Prestige Brands' Dramamine, with as many as 60% indicating that they most often suffer while riding as a passenger in a car.

Although many — 86% — agree that motion sickness is an unpleasant condition that can spoil travel plans, nearly half (46%) admit that they have no idea how to prevent it. 

May 7, 2013

Sato Pharmaceutical, maker of ZenTrip, an over-the-counter motion sickness remedy, recently completed an outdoor urban panel promotion with Duane Reade drug stores in New York, driving trial to the remedy’s thin-film medicated strip.

CARSON, Calif. — Sato Pharmaceutical, maker of ZenTrip, an over-the-counter motion sickness remedy, recently completed an outdoor urban panel promotion with Duane Reade drug stores in New York, driving trial to the remedy’s thin-film medicated strip.

Street-level displays were strategically placed throughout New York at subway entrances to reach multiple audiences with increased frequency, noted Russ Allison, Sato general manager U.S. 

November 1, 2012

The global market for treatments for neurodegenerative disorders will exceed $20 billion before the end of the decade, according to a new report.

FARMINGTON, Conn. – The global market for treatments for neurodegenerative disorders will exceed $20 billion before the end of the decade, according to a new report.

Global Information announced the availability of four research reports that analyze the global markets for treatments for syndromes of progressive ataxia and weakness disorders. According to GII, the global market for treatments was nearly $14 billion and is expected to reach $23.5 billion by 2017, after increasing at a five-year compound annual growth rate of 9.4%.

October 15, 2012

NASA's Johnson Space Center and Epiomed Therapeutics have signed an agreement to develop and commercialize a NASA-crafted, fast-acting nasal spray to fight motion sickness.

HOUSTON — NASA's Johnson Space Center and Epiomed Therapeutics have signed an agreement to develop and commercialize a NASA-crafted, fast-acting nasal spray to fight motion sickness. 

August 28, 2012

Merz announced it has acquired a medication designed to treat a condition associated with such neurologic conditions as cerebral palsy.

GREENSBORO, N.C. — Merz announced it has acquired a medication designed to treat a condition associated with such neurologic conditions as cerebral palsy.

July 23, 2012

A drug made by Pfizer for treating pain disorders doesn't affect men's reproductive functions, according to a new post-approval clinical study.

NEW YORK — A drug made by Pfizer for treating pain disorders doesn't affect men's reproductive functions, according to a new post-approval clinical study.

The drug maker announced Monday the results of study A0081104 of Lyrica (pregabalin), which compared the drug with placebo in healthy males to assess its effects on sperm production. The phase-4 study was required by the Food and Drug Administration.

July 5, 2012

The Food and Drug Administration has approved Lupin Pharmaceuticals' generic version of a drug used to treat pain and seizure disorders.

BALTIMORE — The Food and Drug Administration has approved Lupin Pharmaceuticals' generic version of a drug used to treat pain and seizure disorders.

Lupin announced the approval of pregabalin capsules in the 25-mg, 50-mg, 75-mg, 100-mg, 150-mg, 200-mg, 225-mg and 300-mg strengths. The drug is used to treat fibromyalgia, partial-onset seizures in adults, neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia.

June 21, 2012

The Food and Drug Administration has approved a new indication for a Pfizer drug.

NEW YORK — The Food and Drug Administration has approved a new indication for a Pfizer drug.

Lyrica (pregabalin) capsules CV now can be used for the management of neuropathic pain associated with spinal cord injury. The drug received a priority review designation for this new indication as more than 100,000 patients — approximately 40% of the 270,000 patients with spinal cord injury in the United States — suffer from this chronic, complex pain condition.

June 19, 2012

The Food and Drug Administration has declined to approve a drug designed to treat a rare, progressive and fatal neurodegenerative disease.

NEW YORK — The Food and Drug Administration has declined to approve a drug designed to treat a rare, progressive and fatal neurodegenerative disease.

The FDA issued a complete response letter to Pfizer pertaining to the company's new drug application for tafamidis meglumine, requesting the completion of a second efficacy study to establish substantial evidence of effectiveness prior to an approval. The agency also has asked for additional information on the data within the current tafamidis NDA.

June 1, 2012

An experimental drug for multiple sclerosis produced a noticeable reduction in symptoms of the disease in a late-stage clinical trial, the drug's developer said Friday.

CAMBRIDGE, Mass. — An experimental drug for multiple sclerosis produced a noticeable reduction in symptoms of the disease in a late-stage clinical trial, the drug's developer said Friday.

Genzyme, a unit of French drug maker Sanofi, announced results from a phase-3 study of Aubagio (teriflunomide) in patients with relapsing forms of MS. According to the study, patients taking the drug in the 14-mg strength experienced a 36.3% reduction in annualized relapse rates and 31.5% reduction in the risk of sustained accumulation of disability over a 12-week period.

May 29, 2012

Generic drug maker Watson Pharmaceuticals has entered a settlement that will allow it to launch a generic patch used to treat post herpetic neuralgia, a pain disorder associated with shingles.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has entered a settlement that will allow it to launch a generic patch used to treat post herpetic neuralgia, a pain disorder associated with shingles.

Watson announced Tuesday a settlement through one of its subsidiaries with Endo Pharmaceuticals and Teikoku Seiyaku Co. over its generic version of Lidoderm (lidocaine) topical patch. Lidoderm had sales of $1.2 billion during the 12-month period ended in March 2012, according to IMS Health.

May 17, 2012

Prestige Brands on Thursday morning announced the launch of Dramamine for Kids.

IRVINGTON, N.Y. — Prestige Brands on Thursday morning announced the launch of Dramamine for Kids, noting that 34% of households (with children between the ages of 2 years and 12 years) have a child with motion sickness. According to the company, it is estimated that one-third of moms currently are using a Dramamine adult formula but would prefer a pediatric product.

April 6, 2012

Sam's Club is offering free screenings for brain health at all of its stores that operate pharmacies this month, the retailer said Friday.

BENTONVILLE, Ark. — Sam's Club is offering free screenings for brain health at all of its stores that operate pharmacies this month, the retailer said Friday.

The company, which has performed more than 1 million health and wellness screenings at it stores since 2011, said it would offer the screenings on April 14 for members and the public, including a memory test and educational materials on Alzheimer's and dementia provided by the Alzheimer's Foundation of America, as well as body mass index, blood pressure and glucose tests.

April 4, 2012

The Food and Drug Administration has approved a patch for treating restless legs syndrome and Parkinson's disease.

ATLANTA — The Food and Drug Administration has approved a patch for treating restless legs syndrome and Parkinson's disease.

UCB announced the FDA approval of Neupro (rotigotine) transdermal system advanced-stage idiopathic Parkinson's and moderate-to-severe restless legs syndrome.

April 3, 2012

Psi Bands, stylish drug-free wristbands for the relief of nausea, were voted the most buzz-worthy product of the year at the Travel Goods Association trade show held in Las Vegas, the company announced earlier this month. The "Buzz Award" is given once per year to the product that has created the most "buzz" at the Travel Goods Show's New Products Pavilion as voted on by retailers and members of the press.

PACIFIC GROVE, Calif. — Psi Bands, stylish drug-free wristbands for the relief of nausea, were voted the most buzz-worthy product of the year at the Travel Goods Association trade show held in Las Vegas, the company announced earlier this month. The "Buzz Award" is given once per year to the product that has created the most "buzz" at the Travel Goods Show's New Products Pavilion as voted on by retailers and members of the press.

March 9, 2012

A Food and Drug Administration panel will meet Monday to discuss a class of drugs designed to treat chronic painful conditions that currently are under development and the safety issues possibly related to the drugs.

WASHINGTON — A Food and Drug Administration panel will meet Monday to discuss a class of drugs designed to treat chronic painful conditions that currently are under development and the safety issues possibly related to the drugs.

February 15, 2012

The Food and Drug Administration will review a regulatory approval application from Pfizer for a drug to treat an extremely rare and fatal degenerative disease, Pfizer said Wednesday.

NEW YORK — The Food and Drug Administration will review a regulatory approval application from Pfizer for a drug to treat an extremely rare and fatal degenerative disease, Pfizer said Wednesday.

Pfizer announced that the FDA had accepted its application for tafamidis meglumine, a treatment for transthyretin familial amyloid polyneuropathy. The disease, also known as TTR-FAP, is a fatal genetic illness that affects about 8,000 people worldwide and causes severe sensory loss, pain, weakness and organ dysfunction.

February 1, 2012

Impax Pharmaceuticals said Wednesday that it obtained exclusive U.S. commercial rights to a drug for migraine headaches made by AstraZeneca.

HAYWARD, Calif. — Impax Pharmaceuticals said Wednesday that it obtained exclusive U.S. commercial rights to a drug for migraine headaches made by AstraZeneca.

January 26, 2012

Pfizer is partnering with a division of Johnson & Johnson and a charity organization to launch an initiative to award funding to projects designed to improve the diagnostic identification and tracking of Alzheimer's disease.

NEW YORK — Pfizer is partnering with a division of Johnson & Johnson and a charity organization to launch an initiative to award funding to projects designed to improve the diagnostic identification and tracking of Alzheimer's disease.

January 25, 2012

The National Advertising Review Board on Tuesday recommended that Novartis Consumer Health discontinue advertising claims that the company’s Excedrin Extra Strength product starts relieving headache pain faster than Advil.

NEW YORK — The National Advertising Review Board on Tuesday recommended that Novartis Consumer Health discontinue advertising claims that the company’s Excedrin Extra Strength product starts relieving headache pain faster than Advil.

The claims at issue were initially challenged before the National Advertising Division of the Council of Better Business Bureaus by Pfizer Consumer Healthcare, makers of Advil.

January 17, 2012

A late-stage clinical trial to evaluate a drug in Alzheimer's disease patients came up short, the drug's developers said Tuesday.

NEW YORK — A late-stage clinical trial to evaluate a drug in Alzheimer's disease patients came up short, the drug's developers said Tuesday, prompting them to cease its development.

Pfizer and Medivation announced results of the phase-3 "CONCERT" trial of Dimebon (latrepirdine), a trial that had lasted 12 months and enrolled 1,003 patients worldwide. The drug, which the companies have studied since 2009, was originally developed by Soviet Union scientists in the 1980s as an antihistamine.